Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

December 18, 2025

•

1 min read

•

Eli Lilly

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switched to orforglipron from Wegovy maintained all but ... [28021 chars]

Read Original Article

Source: Eli Lilly

Visit Source

Share this article

Twitter Facebook

Back to business news